Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell gel takes on acne in new trial

NCT ID NCT07504822

Disease control Sponsor: Yohanes Firmansyah, dr, MH, MM Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three different gels for mild-to-moderate acne: a standard clindamycin-retinoid combo, a clindamycin-retinoid-dexamethasone combo, and a gel made from stem-cell secretions (secretome). About 189 people will use one of the three gels for 8 weeks. Researchers will check if the secretome gel reduces pimples and improves skin quality as well as or better than the other treatments, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem-cell secretome gel (from human umbilical cord mesenchymal stem cells)
What this could lead to
If it works, this could offer a new, potentially safer topical option for treating mild-to-moderate acne without antibiotics or steroids.
What could go wrong
This is an early-phase (1/2) study with only 189 people, so results may not apply to everyone. The secretome gel is experimental and its long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 15-40 years. * Clinical diagnosis of mild to moderate acne vulgaris on the facial area. * Primary lesion location on the face, with a total lesion count meeting the above criteria. * Not currently using topical or systemic acne therapy within: the past 2 weeks for topical therapy; the past 4 weeks for systemic therapy (oral antibiotics, isotretinoin, or systemic steroids). * Willing to use only the treatment regimen provided by the investigators on the facial area throughout the study period. * Willing to adhere to the scheduled follow-up visits (weeks 0, 2, 4, and 8) and to sign informed consent. Exclusion Criteria: * Presence of other facial skin diseases that may interfere with acne assessment (e.g., rosacea, contact dermatitis, impetigo, fungal infections, herpes, etc.). * History of hypersensitivity or allergy to clindamycin, retinoids, topical corticosteroids, or any components of the secretome gel. * Use of oral isotretinoin within the past 6 months. * Pregnancy or breastfeeding. * History of severe immunological disorders or uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus, severe liver or kidney disease). * Presence of extensive open wounds or active infections on the face. * Undergoing aggressive facial cosmetic procedures within the past 3 months (e.g., ablative laser, deep chemical peeling, dermabrasion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinik Precious Me

    Tangerang, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.